Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Sponsor: Tarsus Pharmaceuticals, Inc.
Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Official title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
700
Start Date
2026-03-09
Completion Date
2027-12
Last Updated
2026-05-01
Healthy Volunteers
Yes
Conditions
Interventions
TP-05 (lotilaner) Low Dose
TP05 administered orally at the protocol-defined preventative dose.
TP-05 (lotilaner) High Dose
TP05 administered orally at the protocol-defined preventative dose.
Placebo
Matching placebo administered orally according to the same dosing schedule as TP05.
Locations (19)
Study Site
Pikesville, Maryland, United States
Study Site
Brookline, Massachusetts, United States
Study Site
Fall River, Massachusetts, United States
Study Site
Minneapolis, Minnesota, United States
Study Site
Marlboro, New Jersey, United States
Study Site
Albany, New York, United States
Study Site
Binghamton, New York, United States
Study Site
Buffalo, New York, United States
Study Site
East Syracuse, New York, United States
Study Site
Middletown, New York, United States
Study Site
New York, New York, United States
Study Site
Rochester, New York, United States
Study Site
Erie, Pennsylvania, United States
Study Site
Hatboro, Pennsylvania, United States
Study Site
Philadelphia, Pennsylvania, United States
Study Site
Pittsburgh, Pennsylvania, United States
Study Site
Pottstown, Pennsylvania, United States
Study Site
West Chester, Pennsylvania, United States
Study Site
Warwick, Rhode Island, United States